Eli Lilly (NYSE:LLY) touted data this week from a Phase III study evaluating its Humulin R U-500 concentrated insulin delivered via Insulet‘s (NSDQ:PODD) investigational Omnipod U-500 device. The company reported that people with Type II diabetes taking Humulin R U-500 using the Omnipod device experienced greater A1c reductions and needed less daily insulin compared to adults […]
Diabetes
Medtronic, IBM Watson Health launch AI-powered diabetes management app
Medtronic (NYSE:MDT), in partnership with IBM Watson Health, this week announced commercial availability of its AI-powered Sugar.IQ diabetes management app. Using artificial intelligence, the Sugar.IQ app evaluates how a user’s blood sugar levels respond to variables such as food intake, insulin dosing and other daily routines. At this year’s meeting of the American Diabetes Association, Medtronic […]
Sensile Medical partners with Verily, Sanofi to develop connected insulin patch pump
Swiss medical device-maker Sensile Medical announced this week that it struck a deal with Verily and Sanofi (NYSE:SNY) to develop and commercialize a connected insulin patch pump. The pre-filled insulin patch pump will be designed primarily for people with Type II diabetes, according to the Olten, Switzerland-based company. Each company brings its own unique strength to […]
One Drop launches blood glucose prediction, decision support features
One Drop this week launched blood glucose prediction and automated decision support features for its mobile app designed to help people manage their diabetes. The company said that the new features will enable its mobile app to give blood glucose predictions up to 12 hours into the future and behavioral recommendations based on those forecasts. […]
Senseonics prices $130m public offering
On the heels of an FDA approval for its implantable continuous glucose monitoring tech, Senseonics‘ (NYSE:SENS) today priced a $130 million underwritten public offering of common stock. The offering, which is slated to close on June 28, also includes a 30-day option for underwriters to buy additional shares of common stock worth up to $19.5 […]
Closed-loop insulin delivery systems shine at annual diabetes meeting
As device-makers, healthcare practitioners and people with diabetes convened at this year’s annual meeting of the American Diabetes Association, one major theme emerged: the industry is catching on to the potential of closed-loop insulin delivery systems. Major medical technology companies, including Medtronic and Insulet, touted data at this year’s meeting demonstrating the benefits of their […]
Valeritas touts positive results for V-Go wearable insulin delivery device
Valeritas (NSDQ:VLRX) shares jumped this morning after the company touted positive results from its Enable study, showing that patients who switched from insulin pens and syringes to the company’s wearable V-Go insulin delivery device experienced improved blood glucose levels and lowered their daily insulin dose. The company presented three posters at this year’s meeting of the […]
Medtronic wins CE Mark for MiniMed 670G hybrid closed-loop insulin system
Medtronic (NYSE:MDT) said today that it won CE Mark approval in the European Union for its MiniMed 670G hybrid closed-loop insulin management system for Type I diabetes patients age 7 and older. Fridley, Minn.-based Medtronic said it has clinical programs under way to back expanded indications for the device, which is designed to continuously monitor regulate […]
Tandem wins FDA nod for insulin pump with predictive low glucose suspend feature
The FDA this week approved Tandem Diabetes Care‘s (NSDQ:TNDM) t:slim X2 insulin pump with a predictive low glucose suspend feature designed to cut the frequency and duration of hypoglycemia. The San Diego, Calif.-based company said that upon launch, its new product will also feature Dexcom‘s (NSDQ:DXCM) G6 continuous glucose monitoring system. Tandem expects that the […]
FDA approves Senseonics’ implantable continuous glucose monitor
The FDA this week approved Senseonics‘ (NYSE:SENS) Eversense continuous glucose monitor for use in people ages 18 and older with diabetes. The device is the first CGM system to feature an implantable sensor that can be worn for up to 90 days. Senseonics’ Eversense device includes a small sensor that is implanted just below the […]